Ocular Therapeutix
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Ocular Therapeutix sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Ocular Therapeutix: 20 sponsored US clinical trials, 2 recruiting.
Ocular Therapeutix sponsors 20 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 15 completed. 10 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Neovascular Age-related Macular Degeneration, with 3 trials.
Top-decile sponsor footprint
Ocular Therapeutix ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
20 total, page 1 of 1
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
NCT07516132
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
NCT07235085
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
NCT06223958
OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)
NCT05814757
A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
NCT05335122
Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration
NCT04989699
A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects
NCT04945824
To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease
NCT04747977
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
NCT04539548
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.
NCT04362670
A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
NCT04050865
A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert
NCT04061044
CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension
NCT04360174
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
NCT02914509
Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension
NCT02312544
Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
NCT02034019
Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
NCT01666210
ReSure Sealant Pivotal Study
NCT01498224
I-ZIP Ocular Bandage Pivotal Study
NCT00774228
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
| Phase 3 | 10 |
What is open in the Ocular Therapeutix pipeline
2 recruiting of 20 indexed (10% open); 15 completed (75%).
Phase mix: 10 late (III/IV) vs 9 early (I/II) (balanced across stages).
Top condition: Neovascular Age-related Macular Degeneration (3 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ocular Therapeutix: open-pipeline peers nationwide
Peers matched on 20 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Ocular Therapeutix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Aimmune Therapeutics · 10% recruiting · 10 trials
- Altria Client Services · 10% recruiting · 10 trials
- Alzheimer's Disease Cooperative Study (ADCS) · 10% recruiting · 10 trials
- Ascension Health · 10% recruiting · 10 trials
Related
What to do with this Ocular Therapeutix page
20 registered trials is a research-attention snapshot, not an endorsement of Ocular Therapeutix or any single study.
- 2 of Ocular Therapeutix's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Neovascular Age-related Macular Degeneration is the condition Ocular Therapeutix studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Neovascular Age-related Macular Degeneration trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ocular Therapeutix pipeline card: 20 registered trials from official public datasets.Report a data error.